| Document |
Document Title |
|
WO/2024/079647A1 |
The present invention relates to a composition comprising at least one psychedelic tryptamine, preferably derived from psychedelic psilocybin mushrooms, more preferably from psychedelic psilocybin mushrooms belonging to the Psilocybe gen...
|
|
WO/2024/081168A1 |
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase ("BTK") inhibitors for treatment of subjects with relapsing multiple sclerosis.
|
|
WO/2024/079471A1 |
A prebiotic oligosaccharide composition for use in reducing the level of ammonia. The composition comprises oligosaccharide compounds, for example galactooligosaccharide compounds, which includes: (a) at least 8 wt% Gal-(β1-3)-Gal-(β1-...
|
|
WO/2024/011135A3 |
Aspects of the disclosure relate to oligonucleotides (e.g., RNAi oligonucleotides such as siRNAs) designed to target DUX4 RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, pa...
|
|
WO/2024/079251A1 |
The present invention relates to the field of food supplementation, in particular to the field of nutraceuticals, more in particular to the use of a composition comprising oleuropein. More specifically, the present invention relates to t...
|
|
WO/2024/079645A1 |
The present invention relates to a composition comprising at least one psychedelic not phosphorylated tryptamine, preferably derived from psychedelic psilocybin mushrooms, more preferably derived from psychedelic psilocybin mushrooms bel...
|
|
WO/2024/078124A1 |
Provided in the present invention is the use of a TDGF1 gene in the preparation of a drug for treating aging-related diseases or reversing cell aging. Compared with the prior art, the present invention has the following advantages: the u...
|
|
WO/2024/080117A1 |
Provided is an oral composition for preventing and/or improving cold symptoms. This oral composition for preventing and/or improving cold symptoms contains euglena algae. It is preferable for the cold symptoms in this case to be one or...
|
|
WO/2024/080435A1 |
The present invention relates to a composition comprising farnesol for promoting the proliferation of muscle stem cells, and, more specifically, to: a composition comprising farnesol, having the effects of promoting the growth of muscle ...
|
|
WO/2024/078517A1 |
A method of treating a glucose-6-phosphate dehydrogenase deregulated disorder in a subject in need thereof, the method involving administering a therapeutically effective amount of oleanolic acid or a conjugate salt thereof or prodrug th...
|
|
WO/2024/079603A1 |
The present invention relates to novel pharmaceutical formulations given by the association of an inhibitor of histone methyltransferase activity and chemotherapeutic drugs for use in the treatment of cancer, in particular of colon cance...
|
|
WO/2024/081932A1 |
Provided are methods for the treatment of spinal muscular atrophy (SMA) in a fetal subject in need thereof comprising administering an amount of risdiplam to a carrier of the fetal subject. Administering the amount of risdiplam to the ca...
|
|
WO/2024/074705A1 |
The present invention relates to a method of enhancing gene therapy by using an enzyme effective to degrade or digest and/or inhibit or reduce effector function of serum antibodies in the subject. More particularly, the subject is one th...
|
|
WO/2024/074483A1 |
The present invention relates to compositions for use in the treatment, amelioration, and or prevention of myotonic dystrophy (DM) including DM1 and DM2. The compounds can disrupt the activity of Lin28 (e.g., Lin28A and/or Lin28B), RNA b...
|
|
WO/2024/074727A1 |
The invention relates to an immune cell engineered to express a chimeric antigen receptor (CAR) which specifically binds Fibroblast Activation Protein (FAP) for use in the treatment of skeletal muscle fibrosis in muscular dystrophies.
|
|
WO/2024/069646A1 |
The present invention relates to an improved process for the preparation of Risdiplam compound of Formula-I. The present invention also relates to novel intermediates of Risdiplam compound of Formula-I and process for the preparation of ...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/068808A1 |
A composition comprises at least two ingredients selected from the group consisting of: Fish oil, L-arginine, Vitamin E, Vitamin C, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B1, Vitamin B2, Folic acid, Biotin, Vitamin B12, and is formu...
|
|
WO/2024/068809A1 |
A composition comprises medium-chain triglycerides (MCT) and at least one ingredient selected from the group consisting of: Fish oil, L-arginine, Vitamin E, Vitamin C, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B1, Vitamin B2, Folic aci...
|
|
WO/2024/072907A1 |
Apelin receptor modulators can improve physical performance, slow progression of age-related frailty, and can reduce age-related muscle weakness in human patients. This disclosure provides methods for treating muscle conditions using a p...
|
|
WO/2024/069613A1 |
A composition containing a therapeutically effective amount of a cannabinoid for the treatment of temporomandibular disorders (TMD) that include temporomandibular joint (TMJ) pain.
|
|
WO/2024/067783A1 |
Provided are a compound represented by formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and use of the compound as an androgen receptor (AR) inhibitor.
|
|
WO/2024/068862A1 |
Disclosed herein are methods of treatment for myasthenia gravis (MG) that involve administering (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid, or a pharmaceutical composition thereof, to a patient suffering from symptoms of M...
|
|
WO/2024/064913A1 |
The present disclosure provides gene therapy vectors, such as recombinant adeno-associated virus (rAAV) for expressing a human micro-dystrophin gene. The present disclosure also provides compositions and methods of using these rAAV to tr...
|
|
WO/2024/063570A1 |
The present invention relates to an antisense oligonucleotide (ASO) that targets myotonic dystrophy protein kinase (DMPK) and use thereof. More specifically, the present invention relates to: an antisense oligonucleotide fused with an ad...
|
|
WO/2024/062135A1 |
The present invention relates to nerve growth factor (NGF) or a mutein thereof for use in the prevention or treatment of spasticity in a subject, wherein preferably said NGF or mutein is administered intranasally to said subject.
|
|
WO/2024/061202A1 |
The present disclosure relates to a double-stranded ribonucleic acid (RNA) for inhibiting HMGB1 gene expression, and a modifier, conjugate and use thereof. Specifically, the present disclosure relates to a double-stranded RNA for inhibit...
|
|
WO/2024/062420A1 |
The invention provides methods for treating a patient with one or more conditions associated with IFNß expression in a patient, the method comprising administering to the patient an anti-IFNß antibody in a dosing regimen sufficient to ...
|
|
WO/2024/064147A1 |
This document relates to methods and materials for treating congenital disorders of glycosylation (CDG; e.g., a phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG)). For example, this document provides methods and materi...
|
|
WO/2024/057192A1 |
Provided are methods for treating fibromyalgia or one or more symptoms thereof, that involve the administration of psilocybin or a metabolite thereof, and related uses. The disclosure in some aspects also relates to methods for identifyi...
|
|
WO/2024/058812A1 |
The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. Particularly, the stable vigabatrin liquid pharmaceutical composition is manufactured as a ready-...
|
|
WO/2024/051843A1 |
A pharmaceutical composition for preventing and treating convalescent stage facial nerve paralysis and a use thereof. The pharmaceutical composition contains any one among or a combination of mannitol, sodium aescinate, acyclovir, valacy...
|
|
WO/2024/052895A1 |
This invention provides in some aspects, combinations, compositions and kits comprising a psychedelic drug and an NMD A receptor agonist and applications and uses of same for treating, reducing the incidence of, reducing the severity of ...
|
|
WO/2024/051847A1 |
The present invention relates to a pharmaceutical composition for preventing and treating facial nerve micro-entrapment syndrome and a use thereof in the treatment of facial nerve micro-entrapment syndrome. The use comprises joint utiliz...
|
|
WO/2024/051845A1 |
The present invention relates to a pharmaceutical composition for preventing and treating sequelae stage facial nerve paralysis. The pharmaceutical composition is selected from one among or a combination of mouse nerve growth factor, mon...
|
|
WO/2024/053761A1 |
The present invention relates to a composition for promoting myoblast proliferation and differentiation containing an aldose reductase inhibitor. The composition can increase muscle regeneration, increase skeletal muscle mass, increase m...
|
|
WO/2024/051844A1 |
The present invention relates to a pharmaceutical composition for preventing and treating acute stage facial nerve paralysis, the composition comprising any one among or a combination of an osmotic diuretic drug, an antiviral drug, an an...
|
|
WO/2024/055007A1 |
Treatments of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), and McArdle's disease, with compositions comprising substituted pyridazinone compoun...
|
|
WO/2024/049191A1 |
The present invention relates to a composition for preventing or treating sarcopenia, comprising a furylthiazole-based compound represented by chemical formula 1 as an active ingredient, and the furylthiazole-based compound has been conf...
|
|
WO/2024/048528A1 |
The present invention provides a mechanosignaling inhibitor containing a substance capable of suppressing the expression or function of LSMEM2 as an active ingredient.
|
|
WO/2024/049188A1 |
The present invention relates to a triazolo thiadiazine-based compound, and a composition for preventing or treating sarcopenia, the composition containing the triazolo thiadiazine-based compound as an active ingredient. The triazolo thi...
|
|
WO/2024/048519A1 |
Provided are: a pyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; a pharmaceutical use thereof, etc. A compou...
|
|
WO/2024/048683A1 |
The present invention provides a novel substance that suitably functions as an Met agonist. The present invention provides an artificial protein that includes an antibody Fc region, where an amino acid represented by SEQ ID NO: 1 is inse...
|
|
WO/2024/047247A1 |
The major objective of the present invention was to develop safe, effective and definitive therapeutic strategies for Amyotrophic Lateral Sclerosis through the innovative approach of base editing. In particular, the inventors have identi...
|
|
WO/2024/043242A1 |
Provided is a drug for preventing or treating heart failure, that is effective and that does not have a blood pressure lowering effect. The present invention pertains to: a pharmaceutical composition for preventing or treating heart fa...
|
|
WO/2024/042160A1 |
The instant invention relates to the use of a substance with sodium-hydrogen antiporter 1 inhibitory activity (NHE1 inhibitor) as active ingredient in a therapeutic agent with sodium-hydrogen antiporter 1 inhibitory activity for the trea...
|
|
WO/2024/040768A1 |
Disclosed in the present invention are a 5-pyridine-1H-indazole compound, a pharmaceutical composition, and a use. The structure of the compound is represented by formula I or II, and also comprised are an isomer or pharmaceutically acce...
|
|
WO/2024/040190A1 |
Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...
|
|
WO/2024/038089A1 |
The instant invention relates to the use of a substance with phosphodiesterase-7 inhibitory activity (PDE7 inhibitor) as active ingredient in a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and preventi...
|
|
WO/2024/038821A1 |
The purpose of the present invention is to provide a composition for ameliorating or preventing frailty and a composition for ameliorating or suppressing the decline in the physical activity capacity that accompanies aging. The present i...
|
